Antiviral Prophylaxis for Hepatitis B Core Antibody Positive Patient Starting TALTZ
For a patient with strong hepatitis B core antibody (anti-HBc) positivity who is HBsAg-negative and starting ixekizumab (TALTZ) for psoriasis, antiviral prophylaxis is conditionally recommended based on moderate-risk classification, though monitoring alone is also acceptable. 1
Risk Stratification
According to the 2025 AGA guidelines, cytokine/integrin inhibitors (which include IL-17 antagonists like ixekizumab) place HBsAg-negative/anti-HBc-positive patients in the moderate-risk category for HBV reactivation (1-10% risk) 1. This is a critical distinction from HBsAg-positive patients, who would be at high risk.
Baseline Testing Required
Before initiating TALTZ, confirm the following serologic markers:
- HBsAg (should be negative in your case)
- Anti-HBc (positive in your case)
- HBV-DNA (essential baseline measurement)
- Anti-HBs (though this does NOT guide prophylaxis decisions per current evidence) 1
Management Options
For moderate-risk patients (HBsAg-negative/anti-HBc-positive on cytokine inhibitors), you have two evidence-based approaches:
Option 1: Antiviral Prophylaxis (Conditional Recommendation)
- Start prophylaxis BEFORE initiating TALTZ
- Continue for at least 6 months AFTER discontinuing TALTZ 1
- Preferred agents: Entecavir or tenofovir (superior resistance profiles for long-term use compared to lamivudine) 2
- This approach is supported by meta-analysis data showing reactivation rates of 4.4% (95% CI: 2.2-8.7%) in HBsAg-negative/HBcAb-positive patients without prophylaxis 3, and 0% with prophylaxis 4, 5
Option 2: Monitoring Alone (Conditional Recommendation)
- HBV-DNA or HBsAg testing every 3 months 1, 6
- ALT/AST monitoring every 3 months 6, 7
- Initiate antiviral therapy immediately if HBV-DNA becomes detectable or rises >1 log10 IU/mL 4
Clinical Decision-Making
The choice between prophylaxis versus monitoring depends on:
- Patient reliability for follow-up: If adherence to quarterly monitoring is uncertain, prophylaxis is safer
- Baseline HBV-DNA level: If detectable at baseline, prophylaxis is strongly preferred
- Severity of consequences: One case series documented death from hepatic failure despite rescue antiviral treatment in an HBsAg-negative/HBcAb-positive patient 3
Evidence Synthesis
The 2025 AGA guideline provides a conditional recommendation for prophylaxis in moderate-risk patients (moderate certainty evidence), acknowledging that both approaches are reasonable 1. However, real-world psoriasis data from 2025 showed zero reactivations in 40 patients who received prophylaxis versus documented reactivations in those who did not 4. A 2022 meta-analysis found the reactivation rate dropped from 26.6% to 0% with antiviral prophylaxis 5.
Critical Caveats
- IL-17 inhibitors have limited long-term data: The AGA guideline specifically notes that data for cytokine inhibitors in HBsAg-negative/anti-HBc-positive patients are still evolving 1, 6
- TALTZ label does not mandate prophylaxis but requires TB evaluation pre-treatment and warns about serious infections 8
- Risk is cumulative with multiple immunosuppressants: If the patient is on or will be on additional immunosuppression, this elevates risk 1
Practical Implementation
If choosing prophylaxis:
- Start entecavir 0.5 mg daily or tenofovir 300 mg daily 2-4 weeks before first TALTZ dose 2
- Continue throughout TALTZ therapy plus 6 months after last dose 1
- Monitor HBV-DNA and transaminases every 3 months regardless 6
If choosing monitoring:
- Check HBV-DNA, HBsAg, and ALT/AST every 3 months
- Have a low threshold to start antivirals if any viral activity detected
- Ensure patient understands warning signs of hepatitis (jaundice, dark urine, severe fatigue)
Given the documented mortality risk in this population and the safety/efficacy of modern antivirals, prophylaxis represents the more conservative approach for real-world practice, particularly if monitoring compliance is uncertain.